2025 poster gallery
-
IgM Monoclonal Gammopathy Arises Directly from MBL/CLL Cells: Evidence from Proteomic Analyses
-
A Phenotypically Distinct Population of CLL Cells with Lower CD20 Expression is Present Within Abdominal Subcutaneous Adipose Tissue of Patients with CLL
-
Ubiquitin-like post-translational modifications may modulate the pathogenesis of chronic lymphocytic leukemia mediated by RRAS2
-
hnRNPU regulates alternative splicing of Cav1.2 calcium channel: implications in ibrutinib-associated ventricular arrhythmia
-
ApoliproteinE induces ferroptosis in chronic lymphocytic leukaemia cells
-
Clonality assessment in multiclonal chronic lymphocytic leukemia using Sanger and next-generation sequencing approaches
-
Clinical characteristics and outcome of chronic lymphocytic leukemia patients with renal involvement in the era of target drugs
-
Epigenetic and transcriptional single-cell profiling reveals CLL-like states in low-count MBL
-
Toll-like receptor 9 signalling is a potential tumour escape mechanism following B-cell receptor targeted treatments in subsets of patients with Chronic Lymphocytic Leukaemia.
-
A Novel Preclinical Mouse Model of Chronic Lymphocytic Leukemia Driven by BCOR Loss in B Cells
-
Evidence For A Pre-Switched Population And Unmutated Immunoglobulin Receptors In IgG-Expressing CLL Stereotyped Subset #4
-
The S100A9/EMMPRIN axis is involved in chronic lymphocytic leukemia progression and offers novel therapeutic opportunities
-
Highlighting a crucial role for EGR2 mutations in CLL pathogenesis and BTKi resistance
-
Monoclonal Gammopathy Defines a Distinct Clinical in Chronic Lymphocytic Leukemia Across Therapeutic Eras
-
Integrating phosphoproteomic analysis and innovative 3D cell culture systems to dissect the role of extracellular stiffness in CLL pathogenesis
-
Long Non-Coding RNA LINC00173 Regulates BCR Signaling Propensity and mRNA Translation via Ribonucleoprotein Granules in CLL Cells
-
Unraveling the NOTCH1/MSI2/c-MYC Signaling Pathway Reveals a Novel Vulnerability in Chronic Lymphocytic Leukemia Progression
-
Immunological Landscape of CLL Development and Response to Early BTK Inhibition in del(13q14) Mice
-
KRAS^G13D-Dependent PI3K/AKT Signaling Regulates Fatty Acid Oxidation in Chronic Lymphocytic Leukemia
-
Normal B Cells in MBL Show Abnormal Transcriptomic and Subset Distributions Compared to Healthy Donors: Evidence for Follicular Maturation in IGHV-Mutated MBL and Extrafollicular Maturation in IGHV-Unmutated MBL
-
Unravelling the Clinical and Biological Features of Accelerated Chronic Lymphocytic Leukemia
-
An immuno-(epi)genomic classification of chronic lymphocytic leukemia refines outcome prediction
-
Unravelling Prognostic Significance: Long-Read Nanopore Sequencing of TP53 and IGHV in Chronic Lymphocytic Leukaemia Patients in Tanzania.
-
Identification and multi-omic characterization of a novel molecular subtype of CLL based on EBF1 expression levels
-
A Multi-Gene Expression-Based Prognostic Model for Risk Stratification in Chronic Lymphocytic Leukemia (CLL)
-
Genomic characterization of chronic lymphocytic leukemia patients with TP53 alterations from a spanish real-world cohort treated with targeted agents
-
Dissecting clonal hematopoiesis in the myeloid compartment of chronic lymphocytic leukemia and Richter transformation
-
CLL10000: Robust Classification of 1172 ATM Variants employing a Five-Factor Score derived from matched Non-Tumor Controls
-
Integrating clinical and genomic factors to predict time to first treatment in chronic lymphocytic leukemia
-
Functional analysis of in-frame variants in TP53 gene identified in adult leukemias: A study of the TP53 Network of European Research Initiative on CLL
-
Artificial Intelligence–Driven Clustering of Peripheral Blood Cell Morphology Reveals Disease Heterogeneity and Prognostic Relevance in CLL
-
Stereotyped BCR Subset #8 in Chinese CLL: Molecular Genetics, Clinical Behaviour, and Prognosis
-
Clonal shifts of TP53 mutations in patients treated with BTK and BCL2 inhibitors: analysis of accompanying genomic changes
-
Clonal Evolutionary Dynamics Shaped by Genetic Profiles in Chronic Lymphocytic Leukemia: A New Era in Disease Monitoring and Therapy Resistance
-
IGHV Next-Generation Sequencing in CLL: Integrating Mutational Status and Clonotype Tracking for MRD Assessment
-
The clinical significance of specific SF3B1 mutation variants in Chinese patients with chronic lymphocytic leukemia
-
Optical genome mapping identifies a high number of chromoanagenesis events in chronic lymphocytic leukemia patients with altered TP53
-
MYD88 Mutations in Chronic Lymphocytic Leukemia Exhibit Distinct Biological Behaviors and Prognostic Implications
-
Serum LC-MS based untargeted metabolomics machine learning for distinguishing asymptomatic and symptomatic CLL/SLL and predicting TTFT
-
IFNγ/IL21-JAK-STAT1 Signaling Axis Drives T-Cell–Mediated CLL Proliferation and Venetoclax Resistance
-
Advanced 3D culture system revealed the dynamic regulation of Podoplanin in CLL cells within the microenvironment
-
SF3B1 K700E Mutation Promotes SAT1-Mediated Metabolic Reprogramming and Suppresses T-cell Immune Response in Chronic Lymphocytic Leukemia
-
EGR2 Hotspot Mutations Drive BTKi Resistance in Chronic Lymphocytic Leukemia via CD27-CD70 Interaction-Mediated T-Cell Exhaustion
-
Investigating the eEF2K/eEF2 axis as a potential target in CLL following nelfinavir treatment
-
Subversion of ERK-MAPK-mediated mRNA translation elongation as a therapeutic strategy in CLL
-
In vitro investigation of the phenotype of CLL cells during trafficking and homing in a 3D-printed bioreactor
-
Selectively targeting foreign antigen to surface membrane IgD leads to enhanced T-cell activation in patients with CLL and normal people
-
Early effects of venetoclax monotherapy on immune cells in patients with chronic lymphocytic leukemia
-
Imaging mass cytometry reveals distinct cellular architectures in proliferative and non-proliferative regions of the chronic lymphocytic leukaemia lymph node tumour microenvironment
-
Unraveling a poor-prognosis CLL subgroup: from IGHV bias and AID activation to altered T-cell profiles
-
High-dimensional profiling of CLL and T cell interactions during early phase of disease using a 42-color full-spectrum cytometry panel
-
Characterizing the Tumor Microenvironment in CLL: The Role of NK Cells and Prognostic Gene Markers
-
Expression and signalling patterns of CD180/MD1 and CD150 in Chronic Lymphocytic Leukaemia (CLL) cells and MEC 1 cell line
-
BIOLOGICAL FEATURES of B-CLL AND RESIDUAL IMMUNITY AT TREATMENT INITIATION DETERMINE IMMUNITY ON BTKI THERAPY.
-
IGHV Repertoire in Israeli CLL Patients Reveals Significant Low Frequency of Stereotyped Subsets – A Single Center Retrospective Study
-
Chronic Lymphocytic Leukemia and Renal Cell Carcinoma: A Case Series of Twelve Patients
-
The Integrin Adaptor Kindlin-3 Regulates Chronic Lymphocytic Leukemia Development and Progression
-
A fraction of lymph node CLL B cells exhibits high expression of T-bet
-
Screening People with Persistent Absolute Lymphocytosis Favors the Identification of High-Count Monoclonal B-Cell Lymphocytosis
-
Clinical and Biological Impact of Plasma Cytokine Levels in Newly Diagnosed Chronic Lymphocytic Leukemia
-
Selective NIK Inhibition Overcomes Microenvironment-Mediated Resistance and Synergizes with Venetoclax in CLL
-
Pevonedistat Enhances the Cytotoxic Effect of Rohinitib on B Cells of Chronic Lymphocytic Leukemia
-
Targeting Lysosomes in the Chronic Lymphocytic Leukemia Microenvironment
-
Linking Cytokine Signaling and Metabolism in Chronic Lymphocytic Leukemia: The Translational Relevance of the IL-12 Family
-
Distinctive Features in NF-kB Regulation Favor a Synergistic Action of Pevonedistat and Laduviglusib on B Cells of Chronic Lymphocytic Leukemia
-
Developing a novel lipid-based imaging tool for the surveillance of chronic lymphocytic leukemia
-
Effects of Pirtobrutinib, a non-covalent BTK inhibitor, on T-cell function in chronic lymphocytic leukemia (CLL)
-
Evaluation of two novel Cyclin Dependent Kinase 9 inhibitors for the treatment of Myeloid Cell Leukaemia 1 (MCL1) high Chronic Lymphocytic Leukaemia
-
Risk of Second Primary Malignancies in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Receiving First-line Therapy: A Real-World Study
-
Cytogenetic instability and therapeutic pressure in Fixed vs Continuous regimens for Chronic Lymphocytic Leukemia after first line treatment: Preliminary Data from an Italian Multicenter Experience
-
Factors Influencing the Regimen choice for firSt-line Therapy in Chronic Lymphocytic Leukemia: the FIRST-CLL study
-
A Phase 2 study with Tafasitamab and Zanubrutinib in newly diagnosed chronic lymphocytic leukemia/small lymphocytic lymphoma – TaZa CLL Study
-
Venetoclax and obinutuzumab in first-line treatment of unfit patients with CLL – real-life data analysis of the Polish Adult Leukemia Group
-
The impact of body mass index on overall survival in chronic lymphocytic leukemia
-
Optimizing Time-Limited Therapy in Unfit CLL/SLL Patients: Orelabrutinib, Bendamustine, and Obinutuzumab Combination (OBG) Regimen
-
Factors influencing physician’s choice of fixed-duration ibrutinib+venetoclax or continuous ibrutinib monotherapy in the treatment of patients with previously untreated CLL: physician questionnaire results from the prospective phase 2 TAILOR study
-
Impact of testing for genetic markers on treatment selection and clinical outcomes among patients with chronic lymphocytic leukemia
-
Outcomes, inequities, and access to front-line preferred therapies for chronic lymphocytic leukemia in the United States: a real-world evidence study
-
Real-world Utilization of Novel Therapies and Overall Survival among U.S. Medicare Beneficiaries Initiating Frontline Chronic Lymphocytic Leukemia Treatment
-
Final analysis of fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia /small lymphocytic lymphoma in the phase 2 CAPTIVATE study
-
Health-related quality of life in patients with previously untreated chronic lymphocytic leukaemia treated with ibrutinib and rituximab or fludarabine, cyclophosphamide and rituximab: patient-reported outcomes from the multicentre, open-label, randomised, phase 3 FLAIR trial
-
CLL18 / MOIRAI: an international phase-III trial aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes in first-line treatment of CLL/SLL
-
Acalabrutinib Monotherapy versus Acalabrutinib plus Obinutuzumab Combination Therapy in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia: A ‘Real-World’ Study of Efficacy and Safety
-
A Refined Continuous Individualized Risk Index (CIRI2-CLL) for Accurately Predicting Outcomes after Limited-Duration CLL Therapy
-
SEQUOIA 5-year Follow-up in Arm C: Frontline Zanubrutinib Monotherapy in Patients with del(17p) and Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
-
Combination of Zanubrutinib + Venetoclax for Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results in SEQUOIA Arm D
-
Safety and Efficacy of Zanubrutinib in a Subgroup of Older Patients (≥75 Years) With Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma From the SEQUOIA Study
-
Risk of Acute Kidney Injury and Cytopenias During Treatment of Chronic Lymphocytic Leukemia in a Nationwide Real-World Cohort
-
MRD-Driven Venetoclax and Rituximab Combination in Previously Untreated Chronic Lymphocytic Leukemia: Results of the Prospective, Multicenter, Phase II Trial of the Polish Adult Leukemia Group (VERITA PALG-CLL5)
-
Safety Analysis of Fixed-Duration Acalabrutinib-Venetoclax Combinations vs Chemoimmunotherapy: A Post Hoc Analysis From the Phase 3 AMPLIFY Trial
-
IGLV3-21R110 as a prognostic marker for early stage CLL patients – clinical implications in patients treated with BTK inhibitors and diagnostic challenges
-
Efficacy and Safety of Zanubrutinib in a Fit Subgroup of Patients with Treatment-Naive Chronic Lymphocytic Leukemia: Post Hoc Analyses from the SEQUOIA Study
-
A Prospective Multicenter Study of FCR Alternating with Ibrutinib in Treatment-naive Patients with chronic lymphocytic leukemia (CLL)
-
A Prospective, Single-Center, Single-Arm Clinical Trial of Zanubrutinib Monotherapy and ZFCG combined therapy was given sequentially for the Treatment of Primary Symptomatic CLL/SLL (Stop Trial)
-
Orelabrutinib, fludarabine, cyclophosphamide and obinutuzumab (OFCG) for first-line treatment of chronic lymphocytic leukemia: a multicenter, investigator-initiated phase II trial (cwcll-001 trial)
-
Assessing measurable residual disease (MRD) by cell-free DNA (cfDNA): results from a real-world series
-
The role of Minimal Residual Disease in chronic lymphocytic leukemia
-
Ibrutinib plus venetoclax with measurable residual disease-guided duration of treatment is superior to both ibrutinib monotherapy and fludarabine-cyclophosphamide-rituximab for previously untreated chronic lymphocytic leukaemia: Report of the Phase III UK NCRI FLAIR study.
-
STATIC TRIAL (Stopping Therapy to Avoid Treatment-resistance In CLL): A randomised phase III trial comparing intermittent with continuous treatment strategies in CLL
-
Absence of lymphocytosis after starting treatment with cBTKi is a rare phenomenon except for trisomy 12 and CD49d positive CLL
-
Real-World Treatment Utilization Patterns, Discontinuation and Healthcare Resource Utilization of First-Line (1L) Bruton Tyrosine Kinase Inhibitor (BTKi) Therapy in Chronic Lymphocytic Leukemia (CLL): Age-Related Disparity
-
Effect of targeted treatment on IGHV subset #2 and #8 patients in CLL: Comparison of MRD defined Ibrutinib plus Venetoclax treatment to the Ibrutinib and FCR arms of the FLAIR Trial
-
Central Nervous System Involvement in Chronic Lymphocytic Leukemia: An International Retrospective Study by ERIC, the European Research Initiative on CLL
-
Ten-year follow-up of a phase II study of ibrutinib in relapsed/ refractory chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL)
-
Transcriptional reprogramming and survival co-dependencies of chronic lymphocytic leukemia resistant to venetoclax
-
A functional prognostic model predicts progression free survival in patients with relapsed chronic lymphocytic leukemia treated with ibrutinib + venetoclax
-
EFFICACY AND TOLERABILITY OF VENETOCLAX PLUS RITUXIMAB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA – REAL-WORLD ANALYSIS OF POLISH ADULT LEUKEMIA STUDY GROUP
-
Sequencing single novel agent-based therapy for patients with CLL: A retrospective study of patients treated with covalent Bruton Tyrosine Kinase inhibitor (cBTKi) followed by B-cell lymphoma 2 inhibitor (BCL2i) versus BCL2i followed by cBTKi
-
Analysis of resistance-related mutations in patients with Chronic Lymphocytic Leukemia treated with BTK or BCL2 inhibitors suggests different underlying resistance mechanisms and subclonal dynamics
-
A Meta-Analysis Investigating Response Rates of Continuous Bruton Tyrosine Kinase Inhibitor Monotherapies in the Treatment of B-Cell Lymphomas
-
Bexobrutideg (NX-5948), a novel Bruton’s tyrosine kinase (BTK) degrader, demonstrates rapid and durable clinical responses in relapsed/refractory CLL: updated findings from an ongoing Phase 1a study
-
Allogeneic stem cell transplantation is effective after pathway inhibitor treatments in CLL – a retrospective study on behalf of the Chronic Malignancies Working Party of EBMT
-
Nemtabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Cohort J of the Phase 2 BELLWAVE-003 Study
-
BELLWAVE-010: An Open-Label, Phase 3 Study of Nemtabrutinib Plus Venetoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
-
Nemtabrutinib in Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Phase 3 BELLWAVE-011 Study
-
Pirtobrutinib after a Covalent BTK Inhibitor in Pretreated Chronic Lymphocytic Leukemia: A Phase 2 Dose Optimization Trial in Progress
-
Comparative Assessment of MRD Detection and Immunological Effects in Relapsed CLL Patients Treated with Rituximab-Venetoclax in real world: Insights from the “Dedalus” Protocol
-
Updated Results From the Phase 1 Study of Sonrotoclax (BGB-11417), a Novel B-Cell Lymphoma 2 Inhibitor, in Combination With Zanubrutinib for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Demonstrate Deep and Durable Responses
-
Re-Treatment with Venetoclax-Obinutuzumab after time-limited, MRD-guided Venetoclax-Obinutuzumab: final analysis of 7 patients with chronic lymphatic leukemia (CLL) treated in the CLL2-BAG trial of the GCLLSG.
-
Real-World Outcomes of Idelalisib in Relapsed/Refractory CLL Including High-Risk Patients and Post-BTKi/BCL2 Therapy: A Single-Center Experience from 2016 to 2025
-
Central nervous system involvement in chronic lymphocytic leukemia: a real-world analysis
-
Unveiling the journey of Chronic Lymphocytic Leukemia patients in Portugal: insights into the Rituximab-Venetoclax protocol
-
MAVRiC: A Phase 2 Study of Mutation-Guided Finite-Duration Acalabrutinib Plus Venetoclax for Relapse After Frontline Finite-Duration Covalent Bruton Tyrosine Kinase Inhibitor Plus Venetoclax‒Based Combination Therapy in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
-
SOUNDTRACK-E: A Phase 1/2 Open-label Multicenter Study to Evaluate the Safety/Efficacy of AZD0486 as Monotherapy or in Combination With Acalabrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
-
Patient-Reported Outcomes (PRO) among Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) receiving Pirtobrutinib: Final Analysis from the BRUIN Phase 1/2 Study
-
Updated Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results From the Ongoing Phase 1 CaDAnCe-101 Study
-
Ibrutinib and acalabrutinib in the treatment of relapsed/refractory chronic lymphocytic leukemia: a real-world analysis from the Czech Chronic Lymphocytic Leukemia Patients Registry
-
Ibrutinib can be effective even at the lowest dose after 10 years of treatment
-
Estimating the Cardiac Deaths Associated with Treating Chronic Lymphocytic Leukemia with Ibrutinib versus Zanubrutinib in the United States
-
Prevalence of BTK, PLCG2, and BCL2 mutations in CLL patients in Croatia – KROHEM study
-
Central Nervous System Involvement in Patients with Richter Transformation
-
Venetoclax in combination with chemotherapy in Richter Syndrome patients: a real-life experience
-
Single-cell transcriptome analysis reveals molecular mechanism of stem-like cells in Richter Transformation
-
The CDK2/9 inhibitor fadraciclib in Richter transformation
-
Phase 2 study of the combination of lisocabtagene maraleucel, nivolumab, and ibrutinib in Richter’s transformation – NCT05672173
-
Development and evaluation of a selection-algorithm optimised ensemble model for predicting infection risk in CLL using structured and unstructured electronic patient record data
-
Immune Cytopenia with Chronic Lymphocytic Leukemia: A Real-World Clinical Characteristic Analysis
-
Targeting immunoglobulin deficiency in CLL: A retrospective evaluation of IgM/IgA-enriched IVIg use in a small cohort of patients from Argentina
-
Feasibility of an individualized physical activity Intervention in CLL patients receiving ibrutinib +/-venetoclax: preliminary results from the QOLIBRI Study
-
Inequalities in the diagnosis and survival of 30,071 people consecutively diagnosed with chronic lymphocytic leukaemia in England between 2014 and 2021: preliminary analysis from the UNCOVER Study Group
-
A Qualitative Study to Explore the Patient Experience of Continuous Covalent Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Study Methodology
-
Evaluating CLL/SLL Clinical Trials: A Participation-to-Prevalence Analysis Using Institutional and SEER Data from 2012-2024
-
Chronic Obstructive Pulmonary Disease and Previous Pneumonia have an impact on infectious complications in patients with Chronic Lymphocytic Leukemia treated with Acalabrutinib and Zanubrutinib: a Multicentre SEIFEM Study.
-
Impact of Dose Intensity of Ibrutinib on Clinical Outcomes of CLL Patients: Analysis of the EVIdeNCE Study
-
A nomogram for survival prediction based on socioeconomic factors in patients with chronic lymphocytic leukemia: an analysis of SEER database
-
A 3 week pause versus continued BTKi during vaccination (IMPROVE): a randomised, open-label, superiority trial.
-
Other Cancers in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
-
An assessment of NK and T cell functional immunity in response to vaccination whilst taking acalabrutinib or ibrutinib monotherapy.
-
Trends and Predictors of Engagement in Preventive Health Measures in Patients with Chronic Lymphocytic Leukemia: A Prospective Analysis of Vaccinations and Cancer Screening Practices
-
Real-World Outcomes Following Pemivibart (Pemgarda™) for COVID-19 Prophylaxis in Immunocompromised Patients with Hematologic Malignancies
-
Incidence of second primary malignancies in Chronic lymphocytic leukemia
-
MVA-based GEO-CM04S1 vaccine results in improved cellular immune response in patients with chronic lymphocytic leukemia (CLL) compared with mRNA-based vaccine: initial results of a Phase II randomized study
-
Targeting BTKi-Resistant CLL Using the Dual Irreversible/Reversible 4th Generation BTK Inhibitor Rocbrutinib
-
Targeting SF3B1 Disrupts Chronic Lymphocytic Leukemia Survival via PFKFB-mediated Glycolytic Dependency
-
Real-world Treatment Outcomes among Patients with High-Risk CLL/SLL Receiving Venetoclax-Based Therapy in 1L or 2L: An Updated International Study
-
BRD4 maintains the surface phenotype of Chronic Lymphocytic Leukemia cells
-
Targeting the p53/xCT/GSH axis with PRIMA-1Met combined with Sulfasalazine shows therapeutic potential in Chronic Lymphocytic Leukemia
-
Dual mTORC1/2 Inhibition by Torin 2 Induces Cytotoxic and Cytostatic Effects in In Vitro Models of Chronic Lymphocytic Leukaemia
-
Therapeutical potential of NRF2 inhibition by Brusatol in Chronic lymphocytic leukemia and in combination with current therapy
-
Setting a 3D model to study Chronic Lymphocytic Leukemia
-
Similarities and Differences in Immune Modulation by Acalabrutinib and Zanubrutinib in Chronic Lymphocytic Leukemia
-
Impact of treatment with ibrutinib or venetoclax on CAR-T cell generation in patients with chronic lymphocytic leukemia. Interim analysis of the GIMEMA CLL2020 study
-
Hematopoietic Progenitor Kinase-1 (HPK-1) Inhibition Improves the In Vitro Efficacy of Bispecific Antibodies in CLL
-
Development and implementation of a novel flow cytometry CD19-agnostic MRD assay in CLL, including in patients treated with anti-CD19 antibody tafasitamab
-
Fibroblast mediated Modulation of bispecific Antibody Treatment in Chronic Lymphocytic Leukemia
-
Autoimmune cytopenias in patients with chronic lymphocytic leukemia receiving acalabrutinib treatment.
-
Number Needed to Treat Analyses of Zanubrutinib vs Acalabrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia
-
A Network Meta-Analysis (NMA) of Efficacy of Zanubrutinib versus Fixed-Duration Acalabrutinib Plus Venetoclax in Treatment-naïve (TN) Chronic Lymphocytic Leukemia (CLL)
-
Comparative Efficacy of Zanubrutinib (ZANU) versus Fixed-Duration Acalabrutinib Plus Venetoclax (AV) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL): A Matching-Adjusted Indirect Comparison (MAIC)
-
Prospective Patient Preference Study for Chronic Lymphocytic Leukemia (CLL) Treatment Attributes Impacting Patient Shared-Decision Making
-
Comparative Analysis of Patients’ Characteristics, Treatment, and Survival Outcomes in CLL from China and the US
-
Improving information provision to enhance chronic lymphocytic leukaemia (CLL) care in resource-limited countries
-
Evaluating Gaps and Opportunities in Chronic Lymphocytic Leukemia Treatment Access: Institutional Capacity Assessments in 18 LMICs
-
Expression of TP53 deletion and Clinical Presentations of Nigerians with Chronic Lymphocytic Leukaemia: A Preliminary Report
-
Understanding the unmet needs in diagnostics and therapeutics of chronic lymphocytic leukemia in Korea
-
A Rare Case of t(8;16)(p11.2;p13.3) and del(17p) That Shows Both Acute Myeloid Leukaemia and Chronic Lymphocytic Leukaemia at the Same Time
-
Efficacy of Fludarabine-based Regimen in the Treatment of Chronic Lymphocytic Leukaemia: A 10-year Comparative Analysis from a Resource-Limited Setting
-
Exploration of Early Signalling Events of CLL upon Exposure to Low Dose Combination of Ibrutinib and Venetoclax
-
Integrated immunogenetic and cytogenetic profiling reveals distinct biological patterns among stereotyped BCR subsets in CLL
-
Investigating 17p-Deletion in Chronic Lymphocytic Leukaemia: A Study of Tumour-Suppressive microRNAs
-
Risk Stratification in Chronic Lymphocytic Leukemia by IgHV Status and Mutational Co-Occurrence Profiling
-
XPO1 Inhibitor Selinexor Induces Heme Oxygenase-1 Mediated p53-Dependent Mitochondrial Ferroptosis in Chronic Lymphocytic Leukemia